腫瘍不可知性NTRK (TRK) 阻害剤
Franklin W Huang1, Felix Y Feng1
1University of California, San Francisco, San Francisco, CA 94158.
Cell
|March 23, 2019
まとめ
ラロトレクトニブは標的がん療法で,NTRK融合を阻害する. FDAの承認は ゲノムの洞察に基づいた 最初の腫瘍不可知症の指標であり 精密な腫瘍学を進めるものです
科学分野:
- 腫瘍学
- 分子生物学
- 遺伝学
背景:
- ラロトレクトニブは小分子キナーゼ阻害剤です.
- ニューロトロフィックチロシン受容体キナーゼ (NTRK) 遺伝子融合を標的とする.
- NTRK融合は様々な癌のタイプに見られます.
研究 の 目的:
- ラロトレクチニブのFDA承認の重要性を強調するためです
- 腫瘍を治す 最初の治療法として 強調するためです
- その指定におけるゲノム洞察の役割を強調する.
主な方法:
- ラロトレクトニブの作用メカニズムのレビュー
- 臨床試験のデータを分析し,その有効性を裏付ける.
- 腫瘍アグノスティック症候群の制御経路の検討
主要な成果:
- ラロトレクチニブは,NTRK融合を持つがんを効果的に標的とする.
- FDAの承認は 腫瘍無効治療の先例を確立しました
- ゲノムプロファイリングは 適格な患者を特定するのに不可欠です
結論:
- ラロトレクトニブは癌治療の パラダイムシフトを象徴しています
- 遺伝子マーカーに基づいた 腫瘍不可知性療法が 望ましい分野です
- 精密医療のアプローチは 腫瘍学的ケアに変革をもたらしています
関連する概念動画
Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Dipeptidyl Peptidase 4 Inhibitors
629
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
629
Antihypertensive Drugs: Direct Renin Inhibitors
1.4K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.4K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.5K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
591
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
591
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
558
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
558


